Biotech Company - Juvenescence Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life
Juvenescence acquires AI drug discovery company Ro5 Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases
Our Pipeline - Juvenescence Our core medicines (JuvTherapeutics) are comprised of therapeutics developed by the Juvenescence team, targeting fundamental aging mechanisms with a near-term age-related first indication identified for clinical development
News - Juvenescence M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases
M42 Announces Strategic Investment and Partnership with Leading Biotech . . . M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases
Jim Mellon - Juvenescence Jim Mellon, a co-founder and Deputy Chairman of Juvenescence, was inspired by the possibilities and advances being made in the area of longevity He travelled across the world, speaking to leading scientists and researchers, and from those conversations, he wrote the book, Juvenescence
Science - Juvenescence SCIENTIFIC APPROACH What Causes Aging? We base our work on breakthrough scientific discoveries that target the underlying biological causes of aging 85% of older adults have at least one chronic health condition, and 60% have at least two We believe that when aging slows, the onset of chronic disease will slow with it Aging Accelerates Chronic
Our Team - Juvenescence Juvenescence Leadership Instrumental In Development Of Medicines With Peak Annual Sales Of $30bn
Dr Gregory Bailey Md - Juvenescence Dr Greg Bailey, MD, a co-founder and the Executive Chairman of Juvenescence, is a physician, financier, and biotech entrepreneur with extensive experience founding and financing healthcare companies Dr Bailey is driven by the important opportunity to truly modify aging based on rigorous science